EuroIntervention | The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

The reference multimedia journal in interventional cardiology

Prediction of delayed conduction disturbances after TAVI

Original Research

Jan 30

Prediction of delayed conduction disturbances after TAVI

Francesco Bendandi, Francesco Saia et al.

This study developed and validated the D-PACE score to predict high-grade atrioventricular block occurring between 24 hours and 30 days after transcatheter aortic valve implantation. The score can identify low-risk patients suitable for next-day discharge.

free

Editorial

Jan 31

Early discharge after TAVI

Stefan Toggweiler

Transcatheter aortic valve implantation (TAVI) complications have declined due to advancements in technology and physician experience, but the increasing number of procedures has strained hospital resources.

free

Original Research

Jan 27

The Neo2 BAV Registry

Andreas Rück, Darren Mylotte, et al.

This retrospective study evaluated the safety and effectiveness of the ACURATE neo2 TAVI system in 181 patients with severe bicuspid aortic valve stenosis, reporting favourable 30-day clinical and echocardiographic outcomes.

free

Original Research

Jan 23

Non-inferiority of Myval versus SAPIEN and Evolut

Niels van Royen, Andreas Baumbach, et al.

The LANDMARK trial found that the Myval transcatheter heart valve series was non-inferior to the SAPIEN and Evolut series in terms of 30-day safety and effectiveness, with better hemodynamic parameters.

Non-inferiority of Myval versus SAPIEN and Evolut

open access

Editorial

Jan 23

A new TAVI contender

Stephan Windecker, Daijiro Tomii

This content covers a wide range of cardiology interventions, including coronary, valvular, heart failure, peripheral, and stroke management approaches.

free

Debate

Jan 20

Drug-coated balloon angioplasty for ISR

Fernando Alfonso, Julinda Mehilli, et al.

In-stent restenosis (ISR) is a common complication of percutaneous coronary intervention. Drug-eluting stents (DES) are recommended over drug-coated balloons (DCB) for treating DES-ISR, but patient-specific factors may guide treatment selection.

NEW ISSUE

Jan 20

A new issue of EuroIntervention

The first online issue of EuroIntervention’s 20th year of publication includes a debate on the pros and cons of drug-coated balloons versus drug-eluting stents in the treatment of in-stent restenosis. In original research: the LANDMARK trial comparing the novel Myval THV versus the balloon-expandable SAPIEN and the self-expanding Evolut THVs; the Neo2 BAV Registry on the use of the ACURATE neo2 THV in treating bicuspid aortic stenosis; the D-PACE score designed to predict delayed conduction disturbances after TAVI as a method for identifying patients eligible for early discharge. Also, in this issue, a flashlight on a post-TAVI late coronary embolism, news from the EAPCI; and more.

Original Research

Jan 16

DOACs versus warfarin in post-STEMI LVT

Yaser Jenab, Behnood Bikdeli, et al.

This randomized trial and pooled analysis compared rivaroxaban and warfarin for left ventricular thrombus resolution in patients with ST-elevation myocardial infarction, suggesting DOACs may be as effective and safe as warfarin.

Meet Cory, your AI Assistant!

Enhance your reading experience and get deeper insights on complex topics.

Learn more

Flashlight

Jan 20

Late coronary embolism post-TAVI

Cristian Ene, Jean-François Argacha, et al.

Editorial

Jan 16

DOACs versus warfarin for left ventricular thrombosis

Felicita Andreotti, Francesco Burzotta

A randomized pilot trial and meta-analysis support the use of rivaroxaban or apixaban instead of warfarin for post-myocardial infarction left ventricular thrombus resolution.

free

Meta-Analysis

Jan 13

Microvascular angina: study enrolment and treatment

Matthew Hammond-Haley, Rasha Al-Lamee, et al.

This systematic review found that only a quarter of studies on the treatment of microvascular angina enrolled patients meeting contemporary diagnostic criteria. There is a lack of high-quality randomized data to support any specific treatment intervention.

Microvascular angina: study enrolment and treatment

Editorial

Jan 3

Next-day discharge post-TAVI: new standard of care?

Giuliano Costa and Sofia Sammartino

The study demonstrates the feasibility and safety of next-day discharge after uncomplicated transcatheter aortic valve implantation (TAVI) procedures, with no significant differences in 30-day readmission rates compared to patients discharged later.

free

Original Research

Jan 13

Polymer-free versus biodegradable-polymer DES

Raffaele Piccolo, Giovanni Esposito, et al.

In all-comer patients undergoing PCI, polymer-free amphilimus-eluting stents were non-inferior to biodegradable-polymer everolimus-eluting stents in terms of a device-oriented composite endpoint at 1-year, but had a higher risk of early stent thrombosis.

Polymer-free versus biodegradable-polymer DES

Editorial

Jan 13

Managing device-related risks

Jens Flensted Lassen, Lisette Okkels Jensen

The content discusses the evolution of percutaneous coronary interventions, including the introduction of balloon angioplasty, bare metal stents, and drug-eluting stents, and the need to balance the risks of restenosis, stent thrombosis, and bleeding.

free

Original Research

Jan 9

Comprehensive diagnosis in CCS patients

Adrián Jerónimo, Javier Escaned, et al.

The study found that the use of an advanced invasive diagnosis (AID) strategy, combining angiography and intracoronary testing, identified a cause of myocardial ischemia in 84.2% of patients with chronic coronary syndromes, compared to 32.2% with invasive coronary angiography alone.